RAHWAY, N.J. & KINGSTON, Ontario–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment … [Read more…]

ZAVZPRET is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine in adults Expands Pfizer’s migraine portfolio, which includes an oral therapy for both acute and preventive treatment, to further meet the needs of people living with this debilitating disease NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) … [Read more…]

Discussion Will Share Insights from Deployment of Advanced Aviation Security Technology BOSTON–(BUSINESS WIRE)–Analogic Corporation announced today that Analogic CEO Tom Ripp will co-present at this year’s Passenger Terminal Expo. The presentation is entitled “Transforming Aviation Security, Staffing, and Passenger Experience.” As airports and airlines seek to rebuild post-Covid-19, a redesign of how passengers experience security … [Read more…]

Donations to Help Families Affected by Childhood Cancer NEW YORK & BARCELONA, Spain–(BUSINESS WIRE)–TransPerfect, the world’s largest provider of language and technology solutions for global business, today announced a 2022 fundraising total of more than €52,000 to benefit the Association of Families and Friends of Oncological Children of Catalonia (AFANOC). TransPerfect employee-led fundraisers for AFANOC … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing” report has been added to ResearchAndMarkets.com’s offering. This report provides you with a landscape description and analysis of chimeric antigen receptor-macrophage (CAR-M) platform technologies and stakeholders from an industry perspective as of February 2023. CAR-M cell therapy is an … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Autoinjectors: Intellectual Property Landscape, Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions, Patent Valuation Analysis, Patentability, Freedom to Operate, Pockets of Innovation, Existing White Spaces, and Claims Analysis” report has been added to ResearchAndMarkets.com’s offering. This report captures some of the key R&D-related trends and provides competitive intelligence on intellectual … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “3D Bioprinting: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions, Patent Valuation Analysis, Patentability, Freedom to Operate, Pockets of Innovation, Existing White Spaces, and Claim Analysis)” report has been added to ResearchAndMarkets.com’s offering. This report captures some of the key R&D-related trends and provides competitive intelligence on … [Read more…]

BALLERUP, Denmark & DUBLIN–(BUSINESS WIRE)–#partnership—LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient … [Read more…]

John H. Owoc will no longer serve in his current role John C. DiDonato announced as Interim CEO PEMBROKE PINES, Fla.–(BUSINESS WIRE)–Vital Pharmaceuticals, Inc. (“VPX Sports” or “Vital” or “Bang Energy” or the “Company”) announced that Founder, Chief Executive Officer (CEO) & Chief Science Officer (CSO), and Chairman John H. Owoc (“Jack”) will no longer … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in China. ICP-248 is a novel, orally bioavailable BCL2 selective inhibitor, which aims to treat … [Read more…]